BPC July 7 updates: Clinical hold placed on JUNO -JCAR015. KITE still on track for Phase 2 ZUMA-1 data + BLA filing 2H 2016. TXMD NDA filing + updates for ALNY CTIX MCRB NVLS PLX

Jul 08, 2016 No Comments by

Updates to the Company Pipeline Database for July 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ALNY 61.52 ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017 CTIX 1.28 Prurisol Placque psoriasis Phase 2b Phase 2b trial to be […]

Daily News Read more

BPC July 1 updates: FDA determines that PTIE DRRX Advisory Committee Meeting is NOT required + ALNY XBIT AEZS updates

Jul 02, 2016 No Comments by

Updates to the Company Pipeline Database for July 1, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AEZS 3.61 Zoptrex Castration and taxane resistant prostate cancer Phase 3 Phase 3 trial to be completed 3Q 2016 ALNY 61.44 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 […]

Daily News Read more

BPC June 9 updates: KMPH PDUFA delay. SPHS rockets 125% after hours following data release + updates for ALNY ARWR CDTX IRWD OTIC VRX

Jun 09, 2016 No Comments by

Updates to the Company Pipeline Database for June 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 65.41 ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016 ARWR 5.99 ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Phase […]

Daily News Read more

FLML FDA Approval + updates for ADRO ALNY ARGS CEMP CERU GNVC MACK MCRB MRNS NWBO PRTK RGLS TBRA TNXP TRVN XNCR

May 03, 2016 No Comments

Updates to the Company Pipeline Database for May 2, 2016, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADRO 13.27 CRS-207 and GVAX Pancreas – ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b top-line data to be released 2Q 2016 ADRO 13.27 CRS-207 and GVAX Pancreas and nivolumab – […]

Read more

APRI data due this month + updates for ABUS ALNY CNAT CYNA GNVC MRTX OGXI ONCE TBPH TRVN XOMA

Mar 09, 2016 No Comments

Updates to the Company Pipeline Database for March 9, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ABUS 3.88 ARB-1467 (TKM-HBV, RNAi) Hepatitis B virus infection (HBV) Phase 2 Phase 2 initiated December 2015.HBsAg reduction results from single dose due 3Q 2016, multiple dose data due 4Q 2016 ABUS […]

Read more

INCY discontinues Phase 3 JANUS trial + updates for GNCA ALNY NAVB

Feb 12, 2016 No Comments

Updates to the Company Pipeline Database for February 11, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 56.96 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 enrolment completed late January 2016. Data due 2017, with NDA to be filed late 2017 assuming […]

Read more

ALNY completes Phase 3 APOLLO enrollment + updates for ARIA CBYL DSCO REPH TENX TTHI

Feb 02, 2016 No Comments

Updates to the Company Pipeline Database for February 1, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 69.75 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 enrolment completed late January 2016. Data due 2017, with NDA to be filed late 2017 assuming […]

Read more

65 pipeline updates predominantly from companies attending the JP Morgan Healthcare Conference

Jan 12, 2016 No Comments

Pipeline updates galore as companies give latest guidance at the JP Morgan Healthcare Conference. Click HERE to register for meeting information and webcasts. Latest updates to the Company Pipeline Database from January 11, 2016. Refer to the FDA Calendar for upcoming catalysts: ACOR 39.98 Dalfampridine Post stroke deficits Phase 2b/3 Phase 3 interim data due 2016 ACOR 39.98 CVT-301 […]

Read more

61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Read more

NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more

MNKD Adcom date set. BDSI Ph3 data due soon. ATHX BOTA offerings. ALNY RIGL pipeline updates + STEM news

Jan 11, 2014 No Comments

MannKind Corporation (Nasdaq:MNKD $5.92) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is tentatively scheduled on April 1, 2014 to review their New Drug Application (NDA) for AFREZZA, for patients with type 1 or type 2 diabetes. The PDUFA date is April 15, 2014. BioDelivery Sciences International, Inc. (NASDAQ: BDSI $6.20) provided a pipeline update as follows: Phase […]

Read more